New RCT Study - Saive Trial - Ivermectin P...
joesixpack
19 Apr 2023
Here is the study.
[link to www.medincell.com (secure)]
From the study:
This study demonstrated highly statistically significant evidence in a large, randomized, double-blind, placebo-controlled study that daily oral treatment with ivermectin reduced the risk of infection following exposure to SARS-CoV-2.
Ivermectin was also shown to be safe in doses and duration higher than currently used in approved indications.
Statistically significant difference was found between active and control groups in terms of risk of infection with SARS-CoV-2 between D1 and D28 post-treatment initiation. Relative Risk Reduction (RRR) was highly statistically significant with 71.57% difference with respectively 30/200 positive cases in ivermectin group and 105/199 in placebo group (mFAS population (399 patients)) with p<0.0001.
News Release from the Medincell website:
Results of the SAIVE study demonstrating good tolerability as well as statistically significant efficacy of Ivermectin vs placebo in the prevention of post-exposure COVID-19 infection will be communicated by MedinCell on April 18, 2023 at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (Copenhagen, Denmark, 15 – 18 April, 2023)
